Main description:

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy discusses recently developed treatments based on molecular targets which are genetically altered in cancer cells and are essential for tumor development and survival. Considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases, and clinical studies performed so far have validated the positive effects of kinase inhibitors for cancer treatment. Each chapter discusses a molecular target, such as ALK2, ATR, CK, Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1.

The book's chapters are written by experts who actively work on the targets to help readers fully understand how they can be used. This is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of novel cancer therapies based on molecular targets.

Contents:

1. Activin receptor-like kinase-2 (ALK2)
2. Ataxia telangiectasia and Rad3-related protein?(ATR)
3. Breakpoint cluster region protein (BCR-AbL)
4. Casein kinase (CK)
5. c-Src kinase/Src-Abl
6. Cyclin dependent kinase 4 and 6
7. Epidermal growth factor receptor (EGFR)
8. Fyn-Blk-Lyn
9. Insulin-like growth factor (IGFs)
10. Mitotic kinesin spindle protein (KSP/Eg5 ATPase)
11. p21-activated kinase 1 (PAK1)
12. p38 mitogen-activated protein (MAP) kinase
13. Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase
14. Rearranged during Transfection (RET)
15. Serine/threonine-protein kinase B-Raf
16. Tubulin polymerization
17. Tumor necrosis factor receptor associated protein 1 (TRAP1)
18. Vascular Endothelial Growth Factor Receptors (VEGFR/PDGFR)